RJ

Reshab Jain

Director Designated Partner DIN 07439066
DIN 07439066 First appointment Mar 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2016
Shareholding value •••• Premium profile

About Reshab Jain

Data last updated:

Reshab Jain was a Designated Partner at Green Star Pharma Llp (2020–2025) and Director at Vanda Melamine Private Limited (2016–2017). The companies operate in Pharma and Home & Lifestyle.

DIN 07439066
Primary Designation Designated Partner
Industry Pharma
First Appointment 04 Mar 2016

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner28 Oct 20202019Active
Vanda Melamine Private Limited U51109DL2016PTC292144
Director04 Mar 20162016₹9.1 Lakh (FY 2023)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Green Star Pharma Llp
Vanda Melamine Private Limited
Premium access

Shareholding and investment profile for Reshab Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Reshab Jain

Reshab Jain was first appointed on 04 Mar 2016 as Director at Vanda Melamine Private Limited. The most recent appointment on record is 28 Oct 2020 at Green Star Pharma Llp.

Reshab Jain held 2 earlier board appointments: Green Star Pharma Llp (Designated Partner, 28 Oct 2020 to 31 Mar 2025); Vanda Melamine Private Limited (Director, 04 Mar 2016 to 25 Dec 2017).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available